Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites

Cancer Biology and Therapy

Volumn 16, Issue 12, 2015, Pages 1726-1737

  El Deiry, Wafik S ^a,c   Vijayvergia, Namrata ^a   Xiu, Joanne ^b   Scicchitano, Angelique ^c   Lim, Bora ^c,d   Yee, Nelson S ^c   Harvey, Harold A ^c   Gatalica, Zoran ^b   Reddy, Sandeep ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b CARIS LIFE SCIENCES   (United States)

^c PENN STATE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

APC; BRAF; c MET; colorectal cancer; Cox2; ERCC1; Her2; irinotecan; KRAS; metastasis; molecular profiling; oxaliplatin; peritoneal cancer; precision medicine; Topo1; TP53

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; IRINOTECAN; TEMOZOLOMIDE; TUMOR MARKER; DNA TOPOISOMERASE (ATP HYDROLYSING);

ADULT; ARTICLE; BRAIN METASTASIS; CANCER INCIDENCE; CANCER LOCALIZATION; COLON CANCER; COLON TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MOLECULAR DYNAMICS; OVARY METASTASIS; PROTEIN EXPRESSION; RECTUM CANCER; SEQUENCE ANALYSIS; TREATMENT PLANNING; AGED; CANCER STAGING; COLORECTAL NEOPLASMS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PERITONEUM TUMOR; SECONDARY;

ADULT; AGED; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE II; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PERITONEAL NEOPLASMS;

EID: 84954561154     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1113356     Document Type: Article

References (57)

1. G.S.Jameson, E.F.Petricoin, J.Sachdev, L.A.Liotta, D.M.Loesch, S.P.Anthony, M.K.Chadha, J.D.Wulfkuhle, R.I.Gallagher, K.A.Reeder, A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat 2014; 147(3):579–88; PMID:25209003; http://dx.doi.org/10.1007/s10549-014-3117-1
2. A.M.Tsimberidou, N.G.Iskander, D.S.Hong, J.J.Wheler, G.S.Falchook, S.Fu, S.Piha-Paul, A.Naing, F.Janku, R.Luthra, Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012; 18(22):6373–83; PMID:22966018; http://dx.doi.org/10.1158/1078-0432.CCR-12-1627
3. A.M.Tsimberidou, S.Wen, D.S.Hong, J.J.Wheler, G.S.Falchook, S.Fu, S.Piha-Paul, A.Naing, F.Janku, K.Aldape, Personalized medicine for patients with advanced cancer in the phase I program at MD anderson: validation and landmark analyses. Clin Cancer Res 2014; 20(18):4827–36; PMID:24987059; http://dx.doi.org/10.1158/1078-0432.CCR-14-0603
4. D.D.Von Hoff, R.K.Ramanathan, M.J.Borad, D.A.Laheru, L.S.Smith, T.E.Wood, R.L.Korn, N.Desai, V.Trieu, J.L.Iglesias, Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29(34):4548–54; PMID:21969517; http://dx.doi.org/10.1200/JCO.2011.36.5742
5. E.Van Cutsem, M.Nowacki, I.Lang, S.Cascinu, I.Shchepotin, J.Maurel, P.Rougier, D.Cunningham, J.Nippgen, C.Köhneet. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 2007; 25(18S):4000
6. J.-Y.Douillard, S.Siena, J.Cassidy, J.Tabernero, R.Burkes, M.Barugel, Y.Humblet, G.Bodoky, D.Cunningham, J.Jassem, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010:JCO. 2009.27. 4860; PMID: 20921465; http://dx.doi.org/10.1200/JCO.2009.27.4860
7. W.S.Samowitz, C.Sweeney, J.Herrick, H.Albertsen, T.R.Levin, M.A.Murtaugh, R.K.Wolff, M.L.Slattery. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65(14):6063–9; PMID:16024606; http://dx.doi.org/10.1158/0008-5472.CAN-05-0404
8. D.L.Aisner, T.T.Nguyen, D.D.Paskulin, A.T.Le, J.Haney, N.Schulte, F.Chionh, J.Hardingham, J.Mariadason, N.Tebbutt, ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res 2014; 12(1):111–8; PMID:24296758; http://dx.doi.org/10.1158/1541-7786.MCR-13-0479-T
9. J.Douillard, D.Cunningham, A.D.Roth, M.Navarro, R.D.James, P.Karasek, P.Jandik, T.Iveson, J.Carmichael, M.Alakl, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. The Lancet 2000; 355(9209):1041–7; PMID:10744089; http://dx.doi.org/10.1016/S0140-6736(00)02034-1
10. A.de Gramont, A.Figer, M.Seymour, M.Homerin, A.Hmissi, J.Cassidy, C.Boni, H.Cortes-Funes, A.Cervantes, G.Freyer, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18(16):2938–47; PMID:10944126
11. C.Tournigand, T.André, E.Achille, G.Lledo, M.Flesh, D.Mery-Mignard, E.Quinaux, C.Couteau, M.Buyse, G.Ganem, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22(2):229–37; PMID:14657227; http://dx.doi.org/10.1200/JCO.2004.05.113
12. H.Hurwitz, L.Fehrenbacher, W.Novotny, T.Cartwright, J.Hainsworth, W.Heim, J.Berlin, A.Baron, S.Griffing, E.Holmgren, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 2004; 350(23):2335–42; PMID:15175435; http://dx.doi.org/10.1056/NEJMoa032691
13. L.B.Saltz, S.Clarke, E.Díaz-Rubio, W.Scheithauer, A.Figer, R.Wong, S.Koski, M.Lichinitser, T.S.Yang, F.Rivera, Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26(12):2013–9; PMID:18421054; http://dx.doi.org/10.1200/JCO.2007.14.9930
14. E.Van Cutsem, C.H.Köhne, E.Hitre, J.Zaluski, C.R.Chang Chien, A.Makhson, G.D'Haens, T.Pintér, R.Lim, G.Bodoky, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New Engl J Med 2009; 360(14):1408–17; PMID:19339720; http://dx.doi.org/10.1056/NEJMoa0805019
15. D.Cunningham, Y.Humblet, S.Siena, D.Khayat, H.Bleiberg, A.Santoro, D.Bets, M.Mueser, A.Harstrick, C.Verslype, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med 2004; 351(4):337–45; PMID:15269313; http://dx.doi.org/10.1056/NEJMoa033025
16. J.Tabernero, Y.Takayuki, A.L.Cohn. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015; 16(5):499–508; PMID:25877855; http://dx.doi.org/10.1016/S1470-2045(15)70127-0
17. A.Grothey, E.Van Cutsem, A.Sobrero, S.Siena, A.Falcone, M.Ychou, Y.Humblet, O.Bouché, L.Mineur, C.Barone, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet 2013; 381(9863):303–12; PMID:23177514; http://dx.doi.org/10.1016/S0140-6736(12)61900-X
18. A.P.Venook, D.Niedzwiecki, H.-J.Lenz, F.Innocenti, M.R.Mahoney, B.H.O'Neil, J.E.Shaw, B.N.Polite, H.S.Hochster, J.N.Atkins, CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32:5s, 2014 (suppl; abstr LBA3)
19. D.D.Von Hoff, J.J.StephensonJr, P.Rosen, D.M.Loesch, M.J.Borad, S.Anthony, G.Jameson, S.Brown, N.Cantafio, D.A.Richards, Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28:4877–83; PMID:20921468
20. M.S.Braun, S.D.Richman, P.Quirke, C.Daly, J.W.Adlard, F.Elliott, J.H.Barrett, P.Selby, A.M.Meade, R.J.Stephens, Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008; 26(16):2690–8; PMID:18509181; http://dx.doi.org/10.1200/JCO.2007.15.5580
21. L.X.Qiu, Q.Y.Tang, J.L.Bai, X.P.Qian, R.T.Li, B.R.Liu, M.H.Zheng. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer 2008; 123(10):2384–9; PMID:18729195; http://dx.doi.org/10.1002/ijc.23822
22. E.Shacham-Shmueli, A.Beny, R.Geva, A.Blachar, A.Figer, D.Aderka. Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine? J Clin Oncol 2011; 29(10):e262-5; PMID:21220612; http://dx.doi.org/10.1200/JCO.2010.32.0242
23. W.Gong, X.Zhang, J.Wu, L.Chen, L.Li, J.Sun, Y.Lv, X.Wei, Y.Du, H.Jin, RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 2012; 75(3):374–80; PMID:21889227; http://dx.doi.org/10.1016/j.lungcan.2011.08.003
24. H.L.Zhang, L.Ruan, L.M.Zheng, D.Whyte, C.M.Tzeng, X.W.Zhou. Association between class III beta-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 2012; 77(1):9–15; PMID:22306125; http://dx.doi.org/10.1016/j.lungcan.2012.01.005
25. F.P.O'Malley, S.Chia, D.Tu, L.E.Shepherd, M.N.Levine, D.Huntsman, V.H.Bramwell, I.L.Andrulis, K.I.Pritchard. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res Treat 2011; 128(2):401–9; PMID:21519837; http://dx.doi.org/10.1007/s10549-011-1511-5
26. A.N.Seo, Y.Kwak, D.W.Kim, S.B.Kang, G.Choe, W.H.Kim, H.S.Lee. HER2 Status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PloS One 2014; 9(5):e98528; PMID:24879338; http://dx.doi.org/10.1371/journal.pone.0098528
27. W.S.Lee, Y.H.Park, J.N.Lee, J.H.Baek, T.H.Lee, S.Y.Ha. Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. Cancer Med 2014; 3(3):674–80; PMID:24668895; http://dx.doi.org/10.1002/cam4.228
28. R.K.Ramanathan, J.J.Hwang, W.C.Zamboni, F.A.Sinicrope, H.Safran, M.K.Wong, M.Earle, A.Brufsky, T.Evans, M.Troetschel, Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 2004; 22(6):858–65; PMID:15641483; http://dx.doi.org/10.1081/CNV-200039645
29. E.J.Blok, P.J.Kuppen, J.E.van Leeuwen, C.F.Sier. Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. Clin Med Insights Oncol 2013; 7:41–51; PMID:23471238; http://dx.doi.org/10.4137/CMO.S10811
30. W.J.Kruszewski, R.Rzepko, M.Ciesielski, J.Szefel, J.Zieliński, M.Szajewski, W.Jasiński, K.Kawecki, J.Wojtacki. Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers 2010; 29(5):207–12; PMID:21206005; http://dx.doi.org/10.1155/2010/109063
31. A.Bertotti, G.Migliardi, F.Galimi, F.Sassi, D.Torti, C.Isella, D.Corà, F.Di Nicolantonio, M.Buscarino, C.Petti, A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Disc 2011; 1(6):508–23; PMID:22586653; http://dx.doi.org/10.1158/2159-8290.CD-11-0109
32. C.L.Vogel, M.A.Cobleigh, D.Tripathy, J.C.Gutheil, L.N.Harris, L.Fehrenbacher, D.J.Slamon, M.Murphy, W.F.Novotny, M.Burchmore, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20(3):719–26; PMID:11821453; http://dx.doi.org/10.1200/JCO.20.3.719
33. Y.-J.Bang, E.Van Cutsem, A.Feyereislova, H.C.Chung, L.Shen, A.Sawaki, F.Lordick, A.Ohtsu, Y.Omuro, T.Satoh, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet 2010; 376(9742):687–97; PMID:20728210; http://dx.doi.org/10.1016/S0140-6736(10)61121-X
34. S.M.Sorscher, Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer. Cancer Invest 2011; 29(7):456–9; PMID:21696295; http://dx.doi.org/10.3109/0735907.2011.590569
35. R.K.Ramanathan, J.J.Hwang, W.C.Zamboni, F.A.Sinicrope, H.Safran, M.K.Wong, M.Earle, A.Brufsky, T.Evans, M.Troetschel, et al. Low overexpression of HER-2/Neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin→) and irinotecan as therapy. A phase II trial #, †. Cancer Invest 2004; 22(6):858-65; PMID:15641483; http://dx.doi.org/10.1081/CNV-200039645
36. S.Siena et al. Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial. J Clin Oncol 33, 2015 (suppl 3; abstr 565)
37. Y.L.Klaver, V.E.Lemmens, G.J.Creemers, H.J.Rutten, S.W.Nienhuijs, I.H.de Hingh. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol 2011; 22(10):2250–6; PMID:21345939; http://dx.doi.org/10.1093/annonc/mdq762
38. P.Shen, J.Hawksworth, J.Lovato, B.W.Loggie, K.R.Geisinger, R.A.Fleming, E.A.Levine. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 2004; 11(2):178–86; PMID:14761921; http://dx.doi.org/10.1245/ASO.2004.05.009
39. J.Franko, Q.Shi, C.D.Goldman, B.A.Pockaj, G.D.Nelson, R.M.Goldberg, H.C.Pitot, A.Grothey, S.R.Alberts, D.J.Sargent. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012; 30(3):263–7; PMID:22162570; http://dx.doi.org/10.1200/JCO.2011.37.1039
40. P.Li, Y.J.Fang, F.Li, Q.J.Ou, G.Chen, G.Ma. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Br J Cancer 2013; 108(6):1238–44; PMID:23481186; http://dx.doi.org/10.1038/bjc.2013.83
41. E.Yang, H.J.Kang, K.H.Koh, H.Rhee, N.K.Kim, H.Kim. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 2007; 121(3):567–75; PMID:17397030; http://dx.doi.org/10.1002/ijc.22706
42. Von Hoff, D.D., M. Hidalgo, et. al. (2011) “Gemcitabine plus nabpaclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.” J. Clin. Oncol.DOI: 10.1200/JCO.2011.36.5742.; PMID: 21969517
43. D.D.Von Hoff, T.Ervin, F.P.Arena, E.G.Chiorean, J.Infante, M.Moore, T.Seay, S.A.Tjulandin, W.W.Ma, M.N.Saleh, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl J Med 2013; 369(18):1691–703; PMID:24131140; http://dx.doi.org/10.1056/NEJMoa1304369
44. M.Hidalgo, C.Plaza, M.Musteanu, P.Illei, C.B.Brachmann, C.Heise, D.Pierce, P.P.Lopez-Casas, C.Menendez, J.Tabernero, SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial. Clin Cancer Res 2015; http://dx.doi.org/10.1158/1078-0432.CCR-14-3222
45. Clinical Trials.gov. 2015 [cited 2015 Mrch 31]; Available from: https://clinicaltrials.gov/
46. Z.S.Zeng, M.R.Weiser, E.Kuntz, C.T.Chen, S.A.Khan, A.Forslund, G.M.Nash, M.Gimbel, Y.Yamaguchi, A.T.Culliford4th, c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 2008; 265(2):258–69; PMID:18395971; http://dx.doi.org/10.1016/j.canlet.2008.02.049
47. M.L.Sundermeyer, N.J.Meropol, A.Rogatko, H.Wang, S.J.Cohen. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 2005; 5(2):108–13; PMID:16098251; http://dx.doi.org/10.3816/CCC.2005.n.022
48. A.Birnkrant, J.Sampson, P.Sugarbaker. Ovarian metastasis from colorectal cancer. Dis Colon & Rectum 1986; 29(11):767–71; PMID:3533472; http://dx.doi.org/10.1007/BF02555331
49. R.G.Moore, M.Chung, C.O.Granai, W.Gajewski, M.M.Steinhoff. Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol 2004; 93(1):87–91; PMID:15047218; http://dx.doi.org/10.1016/j.ygyno.2003.12.039
50. D.Goéré, C.Daveau, D.Elias, V.Boige, G.Tomasic, S.Bonnet, M.Pocard, C.Dromain, M.Ducreux, P.Lasser, The differential response to chemotherapy of ovarian metastases from colorectal carcinoma. Euro J Surg Oncol (EJSO) 2008; 34(12):1335–9; PMID:18455357; http://dx.doi.org/10.1016/j.ejso.2008.03.010
51. P.Huang, T.K.Weber, C.Mendoza, M.A.Rodriguez-Bigas, N.J.Petrelli. Long-term survival in patients with ovarian metastases from colorectal carcinoma. Ann Surg Oncol 1998; 5(8):695–8; PMID:9869515; http://dx.doi.org/10.1007/BF02303479
52. B.Singh, J.A.Berry, A.Shoher, G.D.Ayers, C.Wei, A.Lucci. COX-2 involvement in breast cancer metastasis to bone. Oncogene 2007; 26(26):3789–96; PMID:17213821; http://dx.doi.org/10.1038/sj.onc.1210154
53. F.M.Klenke, M.M.Gebhard, V.Ewerbeck, A.Abdollahi, P.E.Huber, A.Sckell. The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer 2006; 6:9; PMID:16409625; http://dx.doi.org/10.1186/1471-2407-6-9
54. J.Stoehlmacher, H.J.Lenz. Cyclooxygenase-2 inhibitors in colorectal cancer. Semin Oncol 2003; 30(3 Suppl 6):10–6; PMID:12802790; http://dx.doi.org/10.1016/S0093-7754(03)00120-9
55. M.J.Edelman, D.Watson, X.Wang, C.Morrison, R.A.Kratzke, S.Jewell, L.Hodgson, A.M.Mauer, A.Gajra, G.A.Masters, Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy–Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008; 26(6):848–55; PMID:18281656; http://dx.doi.org/10.1200/JCO.2007.13.8081
56. J.Tie, L.Lipton, J.Desai, P.Gibbs, R.N.Jorissen, M.Christie, K.J.Drummond, B.N.Thomson, V.Usatoff, P.M.Evans, KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 2011; 17(5):1122–30; PMID:21239505; http://dx.doi.org/10.1158/1078-0432.CCR-10-1720
57. R.Dienstmann, D.Serpico, J.Rodon, C.Saura, T.Macarulla, E.Elez, M.Alsina, J.Capdevila, J.Perez-Garcia, G.Sánchez-Ollé, Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol Cancer Ther 2012; 11(9):2062–71; PMID:22723336; http://dx.doi.org/10.1158/1535-7163.MCT-12-0290